Skip to content
Catalyst brief · Phase 3 readout · 26 days

VDPHL01: VDPHL01 in Androgenetic Alopecia

Veradermics, Inc. · $MANE · built 19 Nov 2026 from 15 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's quadruple blind design and randomised allocation will help to reduce bias and ensure that the results are reliable and convincing, with the main goal of measuring changes in non-vellus Target Area Hair Counts over 6 months. F3 F4 F5 F6

Base rates

  • Historically, 65.2% of Phase 3 programmes in immunology moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F11
  • The company's past trial-result days had an average absolute share move of 19.9%, which is based on 4 past trial-result days on record. F12
  • The primary completion date is estimated to be Dec 2026, which is 1.0 months later than the date first registered for this trial and 26 days from 19 Nov 2026. F9 F10
  • The company has a record of keeping cash, with $798M in cash and short-term investments as of 30 Sep 2026, which is expected to last about 116 months at the current rate of spending. F13 F14

Filings

  • The company has a cash position of $798M and a runway of about 116 months, which extends well beyond the primary completion date of the trial. F13 F14
  • Insiders have made significant unplanned open-market sales in the last 90 days, totalling $150M. F15
  • The primary completion date of the trial is estimated to be Dec 2026, which is 26 days from the current date. F9

The case for

  • The trial's design, with its quadruple blind and randomised allocation, will help to reduce bias and ensure reliable results, measuring changes in non-vellus Target Area Hair Counts over 6 months. F3 F4 F5 F6
  • The company has a strong cash position, with $798M in cash and short-term investments, which is expected to last about 116 months at the current rate of spending, reducing financial risks associated with the trial. F13 F14
  • The trial is on track to report on time, with the primary completion date estimated to be Dec 2026, which is 26 days from the current date and only 1 month later than initially registered. F9 F10

The case against

  • The trial's large size and multiple study arms may increase the complexity and time required to complete the trial, potentially leading to delays or difficulties in achieving the desired outcomes. F2 F7
  • The trial's primary completion date is estimated to be just 26 days from the current date, which may be overly ambitious and increase the risk of delays or extensions. F9 F10

Open questions

  • Will the trial meet its primary endpoint of changes in non-vellus Target Area Hair Counts?
  • How will the market react to the trial results given the company's history of average absolute share move of 19.9% on past trial-result days?

5 AI sentences were removed by the fact check.

The facts

The trial

  • F1VDPHL01 is a Phase 3 trial of VDPHL01 in Androgenetic Alopecia, sponsored by Veradermics, Inc. (MANE). source ↗
  • F2The trial plans to enrol 480 patients. source ↗

What counts as success

  • F3Main goal as written in the registry: Changes in non-vellus Target Area Hair Counts (TAHC). source ↗
  • F4Blinding: quadruple blind. source ↗
  • F5Allocation: randomised. source ↗
  • F6The main goal is measured over: Month 6. source ↗
  • F7Number of study arms: 4. source ↗

When

  • F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F10That date is 1.0 months later than the date first registered for this trial (Nov 2026). source ↗

Recruitment

Base rates

  • F11Historically 65.2% of Phase 3 programmes in immunology (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F12MANE has had 4 past trial-result days on record, with an average absolute share move of 19.9%. source ↗

Money, insiders and FDA

  • F13MANE reported $798M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F14At the last 12 months' rate of spending (about $7M a month) that cash lasts about 116 months, to around Jun 2036, which is after the registry's primary completion date. source ↗
  • F15Insiders made 4 unplanned open-market sales in the last 90 days, totalling $150M. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.